CytomX Therapeutics (CTMX) 2025 Conference June 05, 2025 02:35 PM ET Speaker0 All right. All right. Welcome, everyone, to Jefferies twenty twenty five Global Healthcare Conference. My name is Roger Sung, one of the senior analysts cover SMICHA Biotech in The US. It is my pleasure to have the next fireside chat with Atomic Therapeutics CEO, Sean. Good. Yeah. Good to see you. Speaker1 Pleasure to be here, Roger. Speaker0 Awesome. Maybe before we start, we know you just announced a very exciting data from your ...

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In ...

CytomX Therapeutics (NASDAQ: CTMX ) is a biotech focused on development of novel immunotherapy approaches for different forms of cancer. In my first coverage of them, I expressed a bullish sentiment primarily onI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of in ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by. Welcome to the CytomX Therapeutics CX-2051 ...

CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.The stock surged after the company reported interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line colorectal cancer (CRC).As of April 7, 25 advanced metastatic CRC patients were treated with CX-2051 across dose levels 1 through 5.CX-2051 was administered on a once every three-week schedule (Q3W).The 2.4 mg/kg and 4.8 mg/kg doses were single-patient dose escalation cohorts that were not anti ...

CytomX Therapeutics (CTMX) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Company Participants Chris Ogden - Chief Financial OfficerSean A. McCarthy - Chairman & CEOWayne Chu - Chief Medical OfficerRobert Driscoll - SVP - Equity ResearchDaniel Smith - Equity Research Associate Conference Call Participants Roger Song - Senior Equity Research AnalystAnupam Rama - AnalystPeter Lawson - Analyst Operator Good morning, everyone, and thank you for standing by. Welcome to the Citemx Therapeutics CX 2,051 phase one ...

Financial Data and Key Metrics Changes - CytomX Therapeutics announced a financing of $100 million with a leading group of healthcare investors, which underscores the confidence in the company's progress and potential [3][7] - The company reported a 28% confirmed overall response rate and a 94% disease control rate for CX-2051 in metastatic colorectal cancer, with a preliminary progression-free survival of 5.8 months [11][26] Business Line Data and Key Metrics Changes - CX-2051, an antibody-drug conjugate targeting EpCAM, has shown promising results in a Phase I clinical trial focused exclusively on metastatic colorectal cancer [11][19] - The trial included a heavily pretreated patient population, with a median of four prior lines of therapy, indicating the drug's potential effectiveness in late-line treatment settings [21] Market Data and Key Metrics Changes - Colorectal cancer is a significant global health issue, with approximately 1.9 million new cases diagnosed annually, expected to rise to over 3 million in the coming decades [7][8] - The current five-year survival rate for metastatic colorectal cancer is only 13%, highlighting the urgent need for innovative treatment options [8] Company Strategy and Development Direction - The company aims to position CX-2051 as a new standard of care in late-line colorectal cancer treatment, with plans to expand its use into earlier lines of therapy [36][37] - There is a vision to explore CX-2051's potential in other solid tumors, leveraging the high expression of EpCAM across various cancer types [37][38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the drug's performance and its potential to transform colorectal cancer treatment, emphasizing the inadequacy of current standard therapies [36][37] - The company plans to generate additional data from ongoing expansions and engage with regulatory authorities to expedite the development process [48][62] Other Important Information - The safety profile of CX-2051 has been favorable, with no dose-limiting toxicities observed to date, and the adverse events reported were manageable and reversible [30][31] - The company is exploring prophylactic strategies to manage gastrointestinal toxicities associated with the treatment [66] Q&A Session Summary Question: What differences are seen between stable disease and responders in terms of baseline characteristics? - Management noted the overall impressive disease control rate and response rate, indicating that they will continue to analyze patient characteristics that may influence outcomes [44][45] Question: What is the current development strategy for pivotal endpoints and moving into earlier lines? - The focus is on generating data from expansion cohorts, with plans to discuss optimal paths for Phase II and potentially Phase III trials with regulatory authorities [48][62] Question: Can you provide details on the management of serious adverse events? - The safety profile is encouraging, and while specific patient details cannot be disclosed, the adverse events reported align with the overall profile [54][55] Question: Are there plans for accelerated development or breakthrough designations? - Discussions with regulatory authorities are anticipated, and the expansion data will be crucial for these conversations [62] Question: Is there evidence of high EpCAM expression in earlier stage patients? - EpCAM is well-established as a CRC target, and its expression is consistent throughout the disease's natural history, supporting its use in earlier treatment lines [71][72] Question: Will higher dosing be considered based on emerging signals? - While the current dose levels are being expanded, the company is cautious about escalating doses without observing dose-limiting toxicities [75][76]

SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before de ...

Financial Performance - Total revenue for Q1 2025 was $50.9 million, a 22% increase from $41.5 million in Q1 2024[7] - Net income for Q1 2025 was $23.5 million, compared to $13.8 million in Q1 2024, representing a 70% increase[16] - Total operating expenses decreased to $28.3 million in Q1 2025 from $29.8 million in Q1 2024, a reduction of 5%[8] - Research and development expenses were $18.9 million for Q1 2025, down 17% from $22.1 million in Q1 2024[9] Cash and Investments - Cash, cash equivalents, and investments totaled $79.9 million as of March 31, 2025, down from $100.6 million as of December 31, 2024[6] - The company’s cash runway has been extended into the second quarter of 2026 due to focused clinical development priorities and cost reductions[10] Clinical Development - CX-2051 Phase 1 dose expansions initiated at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, with additional data expected by Q1 2026[4] - Planning to initiate a Phase 2 study for CX-2051 in advanced colorectal cancer in the first half of 2026[3] - CX-801 Phase 1a translational data in advanced melanoma expected in the second half of 2025[4] Collaborations and Milestones - Astellas collaboration achieved a milestone payment of $5.0 million in February 2025[10]

Core Insights - CytomX Therapeutics announced positive interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line colorectal cancer (CRC) [2][3] - The study demonstrated a 28% confirmed response rate and a median progression-free survival of 5.8 months [1][13] - The company plans to initiate a Phase 2 study in the first half of 2026 [1][13] Patient Characteristics - A total of 25 advanced metastatic CRC patients were treated, with a median of 4 prior lines of therapy [6] - 64% of patients had liver metastases, 64% had KRAS mutations, and 96% were microsatellite stable [6] Efficacy Results - 28% of patients (5 out of 18) achieved confirmed partial responses according to RECIST v1.1 [1][6] - At the highest dose of 10 mg/kg, 43% of evaluable patients (3 out of 7) achieved confirmed partial responses [1][6] - The Disease Control Rate was 94% across the three dose groups [6] Safety Results - CX-2051 was generally well-tolerated with no dose-limiting toxicities observed [1][13] - Most treatment-related adverse events were Grade 1 or Grade 2, with common events including diarrhea, nausea, and fatigue [13] Development Plans - Dose expansions have been initiated at doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg Q3W, with 20 patients expected to be enrolled at each level [13] - Additional Phase 1 data updates are anticipated by Q1 2026, and combination studies in earlier lines of CRC may begin in 2026 [13]